Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Long-Term Investments (2020 - 2025)

Outlook Therapeutics has reported Long-Term Investments over the past 3 years, most recently at $513549.0 for Q4 2025.

  • Quarterly Long-Term Investments fell 22.18% to $513549.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $513549.0 through Dec 2025, down 22.18% year-over-year, with the annual reading at $552183.0 for FY2025, 20.34% down from the prior year.
  • Long-Term Investments was $513549.0 for Q4 2025 at Outlook Therapeutics, down from $552183.0 in the prior quarter.
  • Over five years, Long-Term Investments peaked at $693190.0 in Q3 2024 and troughed at $513549.0 in Q4 2025.